Skip to main content
Axmed

Index finds more pharma companies moving to address access to medicine. Will they now go further?

The 2022 Access to Medicine Index finds that since the COVID-19 pandemic hit, more pharmaceutical companies have stepped up to make some of their products more widely accessible in low- and middle-income countries (LMICs). If the pandemic is to be a turning point in the fight for equitable access to medicine, companies must now scale their efforts to cover more products in their portfolios, and in a greater number of countries.

Related Articles

More stories in the same topic area.

View all